These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

257 related items for PubMed ID: 28778132

  • 1. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
    Andrick BJ, Gandhi A.
    Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
    [Abstract] [Full Text] [Related]

  • 2. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
    Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R, Conti I, Cosaert J, Schwartz GK.
    Lancet; 2016 Jul 30; 388(10043):488-97. PubMed ID: 27291997
    [Abstract] [Full Text] [Related]

  • 3. Olaratumab for advanced soft tissue sarcoma.
    Tobias A, O'brien MP, Agulnik M.
    Expert Rev Clin Pharmacol; 2017 Jul 30; 10(7):699-705. PubMed ID: 28447475
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Olaratumab in the management of advanced soft tissue sarcoma.
    Zobniw CM, Trinh VA, Posey K, Somaiah N.
    J Oncol Pharm Pract; 2019 Mar 30; 25(2):442-448. PubMed ID: 30032714
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP, Penson RT, Gore M, Herraez AC, Peterson P, Shahir A, Ilaria R.
    BMC Cancer; 2018 Dec 27; 18(1):1292. PubMed ID: 30591028
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Olaratumab for the treatment of soft tissue sarcoma.
    Deshpande HA, Cecchini M, Ni Choileain S, Jones R.
    Drugs Today (Barc); 2017 Apr 27; 53(4):247-255. PubMed ID: 28492292
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas.
    Vincenzi B, Badalamenti G, Napolitano A, Spalato Ceruso M, Pantano F, Grignani G, Russo A, Santini D, Aglietta M, Tonini G.
    Crit Rev Oncol Hematol; 2017 Oct 27; 118():1-6. PubMed ID: 28917265
    [Abstract] [Full Text] [Related]

  • 14. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.
    Yonemori K, Kodaira M, Satoh T, Kudo T, Takahashi S, Nakano K, Ando Y, Shimokata T, Mori J, Inoue K, Oakley GJ, Sakaguchi S, Tamura K.
    Cancer Sci; 2018 Dec 27; 109(12):3962-3970. PubMed ID: 30353601
    [Abstract] [Full Text] [Related]

  • 15. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma.
    Martín-Broto J, Pousa AL, Brohl AS, Van Tine BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL.
    Mol Cancer Ther; 2021 Jan 27; 20(1):132-141. PubMed ID: 33177152
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Olaratumab Approved for Soft-Tissue Sarcoma.
    Cancer Discov; 2016 Dec 27; 6(12):1297. PubMed ID: 27827816
    [Abstract] [Full Text] [Related]

  • 18. Olaratumab: First Global Approval.
    Shirley M.
    Drugs; 2017 Jan 27; 77(1):107-112. PubMed ID: 27995580
    [Abstract] [Full Text] [Related]

  • 19. Olaratumab for soft tissue sarcoma.
    Teyssonneau D, Italiano A.
    Expert Opin Biol Ther; 2017 Aug 27; 17(8):1019-1025. PubMed ID: 28691538
    [Abstract] [Full Text] [Related]

  • 20. Olaratumab for the treatment of soft-tissue sarcoma.
    Pender A, Jones RL.
    Future Oncol; 2017 Oct 27; 13(24):2151-2157. PubMed ID: 28745071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.